Sign In
Buy XERS
$5.89
-0.110 (-1.83%)
At Close: Jun 03, 2026
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercial
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01:05pm, Friday, 27'th Nov 2020
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable
Xeris Pharmaceuticals: Marketed Product Company With Platform And Soros Investment Makes Me More Bullish
09:00am, Saturday, 21'st Nov 2020
Last year, I was neutral about the Xeris Pharmaceuticals story; but a lot of positives have happened this year. There's a marketed product, a steadily rising revenue stream, a platform with potential,
Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q3 2020 Results - Earnings Call Transcript
01:15pm, Monday, 09'th Nov 2020
Xeris Pharmaceuticals, Inc. (XERS) CEO Paul Edick on Q3 2020 Results - Earnings Call Transcript
Xeris Pharmaceuticals: Q3 Earnings Insights
07:28am, Monday, 09'th Nov 2020
Shares of Xeris Pharmaceuticals (NASDAQ:XERS) moved higher by 4.6% in pre-market trading after the company reported Q3 results.
